RT Journal Article
T1 Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-COVID-19 Registry
A1 Carrasco-Sánchez, Francisco Javier
A1 López-Carmona, Mª Dolores
A1 Martínez-Marcos, Francisco Javier
A1 Pérez-Belmonte, Luis M.
A1 Hidalgo-Jiménez, Alicia
A1 Buonaiuto, Verónica
A1 Suárez Fernández, Carmen
A1 Freire Castro, Santiago Jesús
A1 Luordo, Davide
A1 Pesqueira Fontan, Paula Maria
A1 Blázquez Encinar, Julio César
A1 Magallanes Gamboa, Jeffrey Oskar
A1 de la Peña Fernández, Andrés
A1 Torres Peña, José David
A1 Fernández Solà, Joaquim
A1 Napal Lecumberri, Jose Javier
A1 Amorós Martínez, Francisco
A1 Guisado Espartero, María Esther
A1 Jorge Ripper, Carlos
A1 Gómez Méndez, Raquel
A1 Vicente López, Natalia
A1 Román Bernal, Berta
A1 Rojano Rivero, María Gloria
A1 Ramos Rincón, José Manuel
A1 Gómez Huelgas, Ricardo
K1 SARS-CoV-2
K1 COVID-19
K1 Hyperglycaemia
K1 Mortality
K1 Diabetes
K1 Hyperglycemia
K1 Hiperglucemia
K1 Mortalidad
AB Background: Hyperglycaemia has emerged as an important risk factor for death in coronavirus disease 2019 (COVID-19). The aim of this study was to evaluate the association between blood glucose (BG) levels and in-hospital mortality in non-critically patients hospitalized with COVID-19.Methods: This is a retrospective multi-centre study involving patients hospitalized in Spain. Patients were categorized into three groups according to admission BG levels: <140 mg/dL, 140-180 mg/dL and >180 mg/dL. The primary endpoint was all-cause in-hospital mortality.Results: Of the 11,312 patients, only 2128 (18.9%) had diabetes and 2289 (20.4%) died during hospitalization. The in-hospital mortality rates were 15.7% (<140 mg/dL), 33.7% (140-180 mg) and 41.1% (>180 mg/dL), p<.001. The cumulative probability of mortality was significantly higher in patients with hyperglycaemia compared to patients with normoglycaemia (log rank, p<.001), independently of pre-existing diabetes. Hyperglycaemia (after adjusting for age, diabetes, hypertension and other confounding factors) was an independent risk factor of mortality (BG >180 mg/dL: HR 1.50; 95% confidence interval (CI): 1.31-1.73) (BG 140-180 mg/dL; HR 1.48; 95%CI: 1.29-1.70). Hyperglycaemia was also associated with requirement for mechanical ventilation, intensive care unit (ICU) admission and mortality.Conclusions: Admission hyperglycaemia is a strong predictor of all-cause mortality in non-critically hospitalized COVID-19 patients regardless of prior history of diabetes. KEY MESSAGE Admission hyperglycaemia is a stronger and independent risk factor for mortality in COVID-19. Screening for hyperglycaemia, in patients without diabetes, and early treatment of hyperglycaemia should be mandatory in the management of patients hospitalized with COVID-19. Admission hyperglycaemia should not be overlooked in all patients regardless prior history of diabetes.
PB Taylor & Francis Group (Informa UK Limited)
SN 0785-3890
YR 2020
FD 2020-11-04
LK http://hdl.handle.net/10668/3212
UL http://hdl.handle.net/10668/3212
LA en
NO Carrasco-Sánchez FJ, López-Carmona MD, Martínez-Marcos FJ, Pérez-Belmonte LM, Hidalgo-Jiménez A, Buonaiuto V. Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-COVID-19 Registry. Ann Med. 2021 Dec;53(1):103-116.
DS RISalud
RD Apr 6, 2025